Biogen, Gilead, Celgene Drugs Get Thumbs Up In Europe
Top-rated biotechs Biogen Idec, Gilead Sciences and Celgene all got good news from Europe Friday, sending their stocks to all-time highs. Biogen’s (BIIB) multiple sclerosis drug Tecfidera moved a step closer to launch in the European Union after it was ruled as a “new active substance” by the EU’s Committee for Medicinal Products for Human Use (CHMP). Under EU rules, a new active substance can be protected from competition for 10